Neurocrine Biosciences (NASDAQ:NBIX) Director Sells $1,197,864.00 in Stock

Key Points

• Director George Morrow sold 7,200 Neurocrine shares for about $1.20 million under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 40.94% to 10,386 shares.
• Neurocrine reported quarterly earnings of $3.29 per share and revenue of $1.12 billion, beating analyst expectations; revenue rose 41.3% year over year. The company also raised its 2026 INGREZZA sales outlook.
• Analyst sentiment remains broadly positive: the stock has a “Moderate Buy” consensus rating and an average price target of $201.55.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director George Morrow sold 7,200 shares of the business's stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $166.37, for a total value of $1,197,864.00. Following the completion of the sale, the director owned 10,386 shares of the company's stock, valued at $1,727,918.82. This trade represents a 40.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Price Performance

NASDAQ NBIX traded up $19.50 on Tuesday, reaching $164.85. The stock had a trading volume of 4,056,875 shares, compared to its average volume of 1,234,742. The company has a market cap of $16.76 billion, a P/E ratio of 24.17, a price-to-earnings-growth ratio of 0.64 and a beta of 0.36. The firm has a fifty day moving average of $146.49 and a two-hundred day moving average of $147.45. Neurocrine Biosciences, Inc. has a 1-year low of $122.14 and a 1-year high of $186.12.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported $3.29 earnings per share for the quarter, topping analysts' consensus estimates of $1.91 by $1.38. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.04 billion. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%. The company's revenue was up 41.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.04 earnings per share. Research analysts predict that Neurocrine Biosciences, Inc. will post 7.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NBIX has been the subject of several analyst reports. TD Cowen lifted their price objective on shares of Neurocrine Biosciences from $200.00 to $220.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Wedbush increased their target price on shares of Neurocrine Biosciences from $185.00 to $194.00 and gave the stock an "outperform" rating in a research report on Monday, August 3rd. Truist Financial raised their target price on shares of Neurocrine Biosciences from $200.00 to $213.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. Mizuho upgraded shares of Neurocrine Biosciences to a "hold" rating in a research report on Wednesday, September 16th. Finally, Wall Street Zen cut Neurocrine Biosciences from a "buy" rating to a "hold" rating in a research note on Sunday, August 9th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $201.55.

Neurocrine Biosciences News Summary

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Quarterly results topped expectations. Revenue increased 41% year over year to $1.12 billion, and earnings were $3.29 per share. Product sales exceeded $1 billion for the first time, with strong demand across the portfolio. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: INGREZZA guidance was raised. Neurocrine now expects 2026 net sales of $2.9 billion to $2.925 billion, reflecting continued demand for its leading product. The company also cited growth from Crenessity. NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View
• Positive Sentiment: Several analysts lifted price targets. Canaccord raised its target to $220 and kept a Buy rating; Piper Sandler raised its target to $215 with an Overweight rating, and RBC raised its target to $190 with an Outperform rating. Canaccord Genuity Group recommendations
• Neutral Sentiment: Neurocrine announced a Phase 2 Alzheimer’s study and plans to present its scientific and neuropsychiatry pipeline at the NEI Fall Congress. These developments may support longer-term pipeline visibility, but no study results were reported. Neurocrine Starts Phase 2 Alzheimer’s Study
• Neutral Sentiment: Morgan Stanley raised its price target to $185 but maintained an Equal Weight rating, signaling a more cautious view than the other target increases. Morgan Stanley recommendations

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at about $2,310,886,000. Renaissance Technologies LLC lifted its stake in shares of Neurocrine Biosciences by 8.0% in the first quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company's stock worth $318,665,000 after acquiring an additional 180,100 shares during the period. First Trust Advisors LP boosted its holdings in Neurocrine Biosciences by 97.0% in the first quarter. First Trust Advisors LP now owns 959,217 shares of the company's stock valued at $126,367,000 after acquiring an additional 472,408 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Neurocrine Biosciences in the second quarter valued at approximately $117,827,000. Finally, Ieq Capital LLC acquired a new stake in Neurocrine Biosciences during the 2nd quarter valued at approximately $107,914,000. Institutional investors and hedge funds own 92.59% of the company's stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company's research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine's leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.